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This paper contributes to the current debate on accounting treatment of R&D expenditures. We 
considered two different measures of future benefits to a firm, sales revenue and operating cash flows. We 
provide evidence that R&D expenditures do not generate more uncertain future sales revenue or 
operating cash flows compared to capital expenditures. In terms of sales revenue, R&D expenditures 
generate significantly less uncertain future benefits compared to capital expenditures. And in terms of 
operating cash flows, our results do not provide conclusive evidence that whether R&D expenditures 
generate more uncertain future benefits than capital expenditures or not. 
 
INTRODUCTION 
 
Our objective in this study is to provide further evidence on the relative degree of uncertainty of 
future benefits attributable to current research and development (R&D) expenditures and to current 
capital expenditures. Kothari, Laguerre, and Leone (hereafter KLL) (2002) consider the uncertainty of 
future earnings in their analysis and find that future earnings from R&D expenditures are more uncertain 
than future earnings from capital expenditures. In addition to the uncertainty of future earnings, we 
examine the uncertainty of future sales revenue and operating cash flows.  The motivation for looking 
into sales revenue stems from the fact that all stakeholders in a firm receive, or expect to receive, a stream 
of income from the firm (Sunder 2008). Total value a firm generates for all of its stakeholders is sales 
revenue. Sales revenue is an important performance measure because it is useful not only as a summary 
measure but also in providing new information to the market (Chandra and Ro, 2008). And investors’, 
lenders’, and other creditors’ expectations about returns depend on their assessment of the amount, 
timing, and uncertainty of future net cash inflows to the entity (FASB SFAC No. 8). Hence we also 
included the uncertainty operating cash flows in our analysis. 
Our study compares the relative contributions of current R&D and capital expenditures to future 
earnings variability, sales revenue variability and operating cash flow variability. We use the standard 
deviation of realized future earnings, sales revenue and operating cash flows as measures for the 
uncertainty of future benefits. We analyze a sample of over 50,000 firm-year observations from 1987 to 
2005 with data on R&D, capital expenditures and estimates of variability in future benefits. We find 
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mixed evidence on the relationship between R&D expenditures and uncertainty of future benefits. 
Specifically, similar to KLL (2002), in a regression of future earnings variability on R&D, capital 
expenditures, and other economic determinants of earnings variability such as leverage and firm size the 
coefficient on R&D is more than three times as large as that on capital expenditures. However, in a 
regression of future sales revenue variability on R&D, capital expenditures, and other economic 
determinants of earnings variability the coefficient on capital expenditures is larger than that on R&D. 
Further, analysis with future operating cash flows variability does not reveal convincing evidence that the 
coefficient on R&D is larger than that on capital expenditures.  
R&D is an important productive input for a significant number of firms (Aboody and Lev, 2000) and 
it has increased significantly during the last few decades. We find that corporate spending on R&D 
increased from $20.4 billion in 1975 to $390.4 billion in 2009 peaking at $467 billion in 2007 for all 
firms in COMPUSTAT database. In 2009, R&D represents 2.7 percent of total assets and 3.9 percent of 
total sales revenue for firms which report R&D on their financial statements. The accounting treatment of 
R&D expenditures requires firms to expense such expenditures in the period incurred (FASB ASC 730-
10-25-1). This treatment of R&D has been a topic of question. FASB employs the degree of uncertainty 
of future benefits as a criterion in determining whether a given cost should be capitalized or expensed. 
And FASB's perceived degree of uncertainty about future benefits from R&D probably commands the 
current accounting for R&D expenditures.  
Studies that suggest the capitalization of R&D or improved R&D disclosures document evidence that 
R&D is associated with future performance (Lev and Sougiannis, 1996; Deng and Lev 2006). 
Additionally, the capitalization (and amortization) of software development costs improves the prediction 
of future earnings (Aboody and Lev, 1998) and extensive product-development and patent protection 
disclosure by biotech IPOs reduces risk evidenced by reduced stock volatility and bid-ask spreads (Guo, 
Lev, and Zhou, 2004). Further, previous studies show that adjusting accounting numbers for capitalization 
of R&D result in increased association between stock prices and accounting numbers (Lev and 
Sougiannis, 1996; Lev, Nissim, and Thomas, 2007). Although, the investors understand the capital 
properties of R&D expenditures they fail to incorporate these benefits fully into stock prices evidenced by 
positive excess stock market returns experienced by firms with high R&D to market value ratio (Chan, 
Lakonishok, and Sougiannis (hereafter CLS), 2001). This is probably due to the current accounting 
treatment of R&D. 
On the other hand, consistent with FASB's concern regarding uncertainty, KLL (2002) provides 
evidence that future benefits from R&D expenditures are more uncertain than future benefits from capital 
expenditures. This relationship is more pronounced in R&D-intensive industries (Amir, Guan, and Livne, 
2007). In addition, firms that have more productive R&D exhibit less volatile future operating 
performance (Pandit, Wasley, and Zach (hereafter PWZ), 2011) which is still higher than the volatility of 
future operating performance from capital expenditures. And for bondholders, when credit risk associated 
with R&D intensive firms is considered, the risks and uncertainties of R&D dominate the future benefits 
(Shi, 2003). Furthermore, excess returns to R&D intensive firms might be due to the risk associated with 
R&D expenditures (Chambers, Jennings, Thompson, 2002). Overall, these studies favor the expensing of 
R&D. 
Our results contribute to the current debate on accounting treatment of R&D expenditures. We 
provide evidence that is contrary to the notion that R&D expenditures generate future benefits that are 
more uncertain than benefits from expenditures in PP&E. The outline for the remainder of the paper is as 
follow. Next section provides the background and motivation for our study. After that we present the 
research design of the paper followed by the results of empirical analysis and our conclusion. 
 
BACKGROUND AND MOTIVATION 
 
Financial Accounting Standards Board (FASB) sets accounting standards in United States that set out 
Generally Accepted Accounting Principles (GAAP). Primary qualitative characteristics of accounting 
information FASB considers in setting standards are relevance and representational faithfulness. GAAP 
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requires R&D expenditures to be expensed in the period incurred (FASB ASC 730-10-25-1) because 
R&D expenditures do not meet the representational faithfulness and the relevance criteria: 
 
“…there is often a high degree of uncertainty about whether research and development 
expenditures will provide any future benefits…” (FASB ASC 730-10-5-3) 
“At the time most research and development costs are incurred, the future benefits are at 
best uncertain. In other words, there is no indication that an economic resource has been 
created... There is normally little, if any, direct relationship between the amount of 
current research and development expenditures and the amount of resultant future 
benefits to the entity…” (FASB ASC 730-10-5-2)  
 
Chartered Financial Analyst (CFA) institute, formerly known as the Association for Investment 
Management and Research (AIMR), is an international, nonprofit organization of more than 70,000 
investment practitioners and educators. As an important body of accounting information users they in 
general concur with FASB’s position on R&D expenditures. For example the following statement 
outlines their position:  
 
“We are not enamored of recording self-developed intangible assets unless their values 
are readily apparent.  We consider the cost of creating them to be so often unrelated to 
their actual value as to be irrelevant in the investment valuation process.  Furthermore, it 
usually is next to impossible to determine in any sensible or codifiable manner exactly 
which costs provide future benefit and which do not.”(AIMR, 1993) 
 
Prior research mostly focused on the relevance of R&D expenditures. Sougiannis (1994) examines 
whether reported accounting earnings reflect benefits from past R&D expenditures. He shows that the 
total effect of past R&D on earnings ranges from 1.559 in 1978 to 2.829 in 1984 with a mean value of 
2.083. He provides evidence that indicate R&D benefits last for seven years. Lev and Sougiannis (1996) 
provide a procedure to estimate depreciation rates for R&D expenditures in each R&D intensive industry. 
Using the procedure they capitalize and amortize R&D expenditures. Their estimates indicate that useful 
life of R&D ranges from five years in Scientific Instruments industry to nine years in Chemicals and 
Pharmaceuticals industry. Eberhart, Maxwell, and Siddique (2004) analyze the future operating 
performance of firms with unexpected R&D increases. They show that value-weighted and equal-
weighted abnormal profit margin for firms that had unexpected R&D increases within the past five years 
is significantly positive. Their evidence indicates that R&D increases lead to better than expected future 
operating performance in terms of profit margin. Hence there is a direct link between a firm's reported 
total R&D, although not for individual R&D projects, and future operating performance. 
While it has been documented that investors on average consider R&D expenditures to be asset 
(Hirschey, 1982; Lev and Sougiannis, 1996), investors fail to incorporate the effect of R&D expenditures 
on future operating performance fully into stock prices, that is R&D is underpriced (Lev and Sougiannis, 
1996; CLS, 2001). Lev and Sougiannis (1996) present evidence that although capitalized R&D 
expenditures are associated with contemporaneous stock prices and returns, capitalized R&D 
expenditures are also associated with subsequent stock returns. Hence they conclude that the 
contemporaneous stock prices do not fully reflect the R&D benefits. CLS (2001) show that the market on 
average fully incorporates R&D benefits into stock prices. However their results indicate that firms with 
high R&D to market value ratio have positive risk-adjusted future excess returns. Eberhart, Maxwell, and 
Siddique (2004) show that long-term abnormal stock return persists after abnormal increases in R&D 
expenditures, which is consistent with investors’ under-reaction to the new information contained in 
increased R&D expenditures. Collectively this evidence suggests that the market is inefficient and the 
inefficiency is due to the investors being misled by conservative accounting for R&D expenditures. 
On the other hand KLL (2002) show that future earnings from R&D expenditures are more uncertain 
than future earnings from capital expenditures. They measure the uncertainty of future earnings as the 
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future earnings variability. Future earnings variability is measured as standard deviation of five future 
annual earnings per share. They demonstrate that future earnings generated by R&D are three times more 
uncertain than future earnings generated by capital expenditures. Further analysis of the relationship 
between R&D expenditures and uncertainty of future benefits reveals that firms that have more 
productive R&D exhibit less volatile future operating performance (PWZ, 2011). Shi (2003) analyzes 
how creditors assess the risks and future benefits of R&D expenditures. The risks of R&D here refer to 
the credit risk and default risk. He shows that R&D is significantly associated with bond default ratings 
and bond premium risk. He also shows that R&D alone approximately explains 80 percent of cross-
sectional variations in bond ratings and bond risk premium. 
Overall, prior research shows that the benefits from past R&D expenditures are reflected in the 
reported accounting earnings but investors fail incorporate these benefits fully into stock prices. And 
these benefits are more uncertain than the benefits from past capital expenditures. In addition creditors 
consider R&D expenditures as risk proxies. 
The main purpose of this paper is to further explore whether the variability of the realizations of 
future benefits is greater due to R&D expenditures than to capital expenditures. We use three different 
proxies for future benefits to a firm: Earnings, Sales revenue, and Operating cash flows. Sunder (2008) 
discusses the value of a firm under neoclassical economic theory and contract theory. Our first measure of 
future benefits to a firm is based on prior literature which follows the neoclassical economic theory of 
firm. In the neoclassical economic theory a firm is seen as an instrument of the entrepreneur or owner. All 
agents, other than the owner, are considered passive in the sense that their behavior can be well 
represented by their respective functions. The owner works with production, supply and demand 
functions to maximize the value of the firm he owns. Value to the owner is the value of the firm (Sunder 
2008). Financial accounting reports are based on the value to the owner. The objective of financial 
reporting is to provide financial information about the reporting entity that is useful to external users in 
making decisions about providing resources to the entity. Hence the primary focus of financial reporting 
is information about an enterprise’s comprehensive income and its components. Investors, creditors, and 
others who are concerned with assessing the prospects for enterprise net cash inflows are especially 
interested in that information (FASB SFAC No. 8). Hence our first measure of benefits generated by a 
company for its investors, to replicate the findings of KLL (2002), is earnings. 
The rationale for our next measure stems from the contract theory of firm. Under the contract-
theoretic view (Barnard, 1936; Simon, 1947; Cyert and March, 1963), a firm is a set of contracts or 
alliances among agents. Each agent contributes factors of production to the firm, and receives 
compensation in the form of cash or other resources in exchange. Each agent chooses to participate in the 
firm if the value of compensation offered by the firm exceeds the opportunity cost of his resource 
contributions. Hence, all stakeholders in a firm receive, or expect to receive, a stream of income from the 
firm (Sunder 2008). These stakeholders would include, but is not limited to, investors, creditors, 
customers, vendors, employees, and government. And the total value a firm generates for all of its 
stakeholders is its sales revenue. We included sales revenue in our analysis as a measure of total benefits 
generated by a company for its stakeholders. 
Sales revenue is an important performance measure for several reasons. Chandra and Ro (2008) 
provide evidence that sales revenue is useful not only as a summary measure but also in providing new 
information to the market. Sales revenue is more useful than earnings in summarizing the performance of 
technology firms and for profit incidents. Although the new information conveyed by earnings has 
declined, the new information conveyed by sales revenue has not. Further, earnings surprises that are 
accompanied by revenue surprises indicate more persistent earnings growth than similar levels of 
earnings surprises not accompanied by revenue surprises (Jagadeesh and Livnat 2006). Last, but not least, 
sales revenue models are less biased, better specified, and more powerful than accrual based models in 
detecting earnings management (Stubben. 2010). 
Prior research provide evidence that demand uncertainty depresses firm investment (Bo, 2002; Fuss 
and Vermeulen, 2004) and this adverse effect of demand uncertainty on R&D investments is sharper than 
that of on non-R&D related investments (Goel and Ram, 2001). Hence we expect firms to invest in R&D 
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projects that would lead to less volatile sales revenue. Thus R&D would generate less uncertain future 
sales revenue than capital expenditures. 
Our last measure of future benefits also follows the neoclassical economic theory of firm. Decisions 
by investors about buying, selling, or holding equity and debt instruments depend on the returns that they 
expect such as dividends, principal and interest payments, or market price increases. Similarly, decisions 
by creditors about providing or settling loans and other forms of credit depend on the principal and 
interest payments that they expect. Hence investors’ and creditors’ expectations about returns depend on 
their assessment of the amount, timing, and uncertainty of future net cash inflows to the entity (FASB 
SFAC No. 8). Although, information about earnings based on accrual accounting usually provides a better 
inference of a firm's ability to generate cash flows, the end goal is assessing the prospects for future net 
cash inflows to a firm. Hence, uncertainty of future net cash inflows would be more relevant to investors 
and creditors than uncertainty of future earnings. Consequently, our last proxy for benefits generated by a 
company for its investors and creditors is operating cash flows. 
Minton and Schrand (1999) provides evidence that higher cash flow volatility leads to lower average 
levels of investment in capital expenditures, R&D, and advertising. And this relationship is strongest for 
R&D after controlling for cash flow levels. Thus firms which rely on R&D for innovation would invest in 
R&D projects that would lead to less volatile cash flows. Hence we expect R&D to generate less 
uncertain future cash flows than capital expenditures. 
 
RESEARCH DESIGN 
 
Empirical Model 
To explore the notion that the variability of future benefits is more sensitive to R&D expenditures 
than capital expenditures, we estimate the following model (firm subscript i is suppressed) from KLL 
(2002): 
 
FIGURE 1 
FUTURE UNCERTAINTY EQUATION 
 
STDEV(FVt+1,t+5?????????1t CapExt ???2t RNDt???3t ADVt ???4t MVt ???5t Leveraget + et+1,t+5 
 
STDEV(FVt+1,t+5) is the standard deviation of future benefits; Proxies for FV are sales revenue (St), 
earnings before extraordinary items and discontinued operations (Et), or operating cash flows (CFt); the 
standard deviation is calculated using five annual observations for years t+1 through t+5; each 
observation is deflated either by the book value of equity, BKV, or by stock price, PRC, at the beginning 
of the period t; CapExt is the capital expenditure per share, deflated by BKV or PRC; R&Dt is research 
and development per share, deflated by BKV or PRC; ADVt is advertising expense per share, deflated by 
BKV or PRC; MVt is the natural logarithm of the market capitalization of equity at the end of year t; and 
Leveraget is the ratio of long-term debt to the market value of equity plus long-term debt, both at the end 
of year t. 
Our focus is on the coefficients of R&D and capital expenditures. However, we include advertising, 
leverage, and market value as control variables which are motivated for inclusion by KLL (2002). Based 
on the results of KLL (2002), we expect advertising and leverage to be positively associated with 
variability of future benefits, while market value of firm is expected to be negatively associated with 
variability of future benefits.  
 
Sample Selection 
We obtain financial data from the Compustat Annual Industrial and Annual Research files for the 
period 1987-2005. For each year t from 1987 to 2005, we retain all observations with non-missing data 
for the following: CapExt is capital expenditures, Compustat data CAPX; RNDt is research and 
development expense, data XRD, a zero reported amount is not treated as a missing value; ADVt is 
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advertising expense, data XAD, a missing value is set to zero; MVt is the market value of equity, 
measured as the natural logarithm of the product of the fiscal-year closing price and common shares 
outstanding [log(PRCC_F*CSHPRI)]; Leveraget is the sum of long-term debt, data DLTT, and debt in 
current liabilities, data DLC, divided by the sum of long-term debt and the market value of equity; Et is 
the primary earnings per share before extraordinary items and discontinued operations, data EPSPX; St is 
sales revenue, data SALE, divided by the number of common shares; CFt is cash flows from operations, 
data OANCF, divided by the number of common shares;  PRC is share price, data PRCC_F; and BKV is 
the stockholders’ equity, data SEQ, divided by the number of common shares outstanding. We exclude 
negative BKV firms when BKV is used as the deflator. 
PRC and BKV are measured at the end of fiscal year t-1 because they are used as deflators. Per share 
values of PRC, BKV, and future benefits, FVt+1 to FVt+5, are adjusted for stock splits and stock dividends 
using the cumulative adjustment factor, Compustat data AJEX, so that they are comparable to the per 
share values of the remaining variables for year t. Our sample period is from 1987 to 2005 since the first 
date when operating cash flows data is available is 1987. And because variability of future benefits is 
calculated using data for five years following year t, the last year of the sample period is 2005.1 
Research intensive firms are likely to go through mergers and acquisitions, and not survive the five 
year period required to calculate variability of future benefits (PWZ, 2011). This would lead to 
survivorship-bias. Even though future benefits variability is calculated using five years of future data, to 
avoid survivor bias, following KLL (2002)'s approach, we do not require future benefits data availability 
for years t+1 to t+5 for a firm-year to be included in the data. In cases where future benefits data are 
missing in any of the periods from t+1 through t+5, the standard deviation of future benefits, 
STDEV(FVt+1,t+5) is set equal to the mean of STDEV(FVt+1,t+5) for the firms in the same Altman Z-Score 
decile portfolio.2 
The ending sample consists of a total of 51,866 firm-year observations when book-value of equity is 
used as the deflator and 51,837 observations when price is used as the deflator. Deflators are used to 
mitigate heteroscedasticity in the regressions. 
 
Descriptive Statistics 
Panel A of Table 1 presents the descriptive statistics for the variables deflated by PRC. We winsorize 
Sales, RND, CapEX, ADV, MV, and leverage at the top and bottom one percent of their distribution each 
year. We winsorize deflated earnings variable at -1 and +1. And, Panel B of Table 1 presents the 
descriptive statistics for the variables deflated by BKV. Average spending for capital expenditures are 
7.38% of their share price and 15.34% of their book value. Firms spend 6.73% of their share price and 
18.49% of their book value on R&D expenditures. Our sample firms are, on average, loss firms. Average 
earnings per share are -0.0574, deflated by PRC, and -0.0668, deflated by BKV. The median earnings are 
positive. Average and median standard deviation of future earnings are similar to those of future cash 
flows. The average (median) standard deviation of future earnings are 0.1359 (0.0936), deflated by PRC, 
and 0.1734 (0.1440), deflated by BKV. And the average (median) standard deviation of future cash flows 
are 0.1310 (0.0955), deflated by PRC, and 0.1873 (0.1554), deflated by BKV. The average standard 
deviation of future sales revenue is much higher than those of earnings and cash flows. 
 
 
 
 
 
 
 
 
 
 
 
Journal of Accounting and Finance vol. 12(3) 2012     153
  
TABLE 1  
DESCRIPTIVE STATISTICS 
 
           Panel (a): Scaled by PRC 
 
 
N 
 
Mean 
Standard 
Deviation 
 
Q1 
 
Median 
 
Q3 
RNDt 51,837 0.0673 0.1094 0.0049 0.0307 0.0824 
CapExt 51,837 0.0738 0.1172 0.0126 0.0363 0.0856 
ADVt 51,837 0.0229 0.0914 0.0000 0.0001 0.0067 
MVt 51,837 -2.2565 2.4038 -3.9861 -2.4572 -0.6767 
Leveraget 51,837 0.2707 0.4437 0.0127 0.1280 0.3621 
Earningst 51,837 -0.0574 0.2567 -0.1049 0.0199 0.0674 
Salest 51,837 2.1427 4.2643 0.3425 0.9702 2.2359 
Cash Flowst 51,837 0.0466 0.2560 -0.0442 0.0478 0.1274 
SD(Et+1,t+5) 51,837 0.1359 0.1252 0.0419 0.0936 0.2043 
SD(St+1,t+5) 51,837 1.0645 1.5649 0.2144 0.5690 1.3022 
SD(CFt+1,t+5) 51,837 0.1310 0.1174 0.0517 0.0955 0.1815 
           Panel (b): Scaled by BKV 
  
N 
 
Mean 
Standard 
Deviation 
 
Q1 
 
Median 
 
Q3 
RNDt 51,866 0.1849 0.3400 0.0119 0.0791 0.2077 
CapExt 51,866 0.1534 0.2370 0.0349 0.0856 0.1760 
ADVt 51,866 0.0417 0.1511 0.0000 0.0005 0.0178 
MVt 51,866 -2.1750 2.3560 -3.8541 -2.3636 -0.6504 
Leveraget 51,866 0.2379 0.3570 0.0090 0.1121 0.3297 
Earningst 51,866 -0.0668 0.4026 -0.2236 0.0456 0.1598 
Salest 51,866 3.3483 4.6971 1.0626 2.1268 3.7668 
Cash Flowst 51,866 0.0083 0.6619 -0.1052 0.1087 0.2647 
SD(Et+1,t+5) 51,866 0.1734 0.1227 0.0823 0.1440 0.2473 
SD(St+1,t+5) 51,866 0.9322 0.9791 0.3219 0.6474 1.2555 
SD(CFt+1,t+5) 51,866 0.1873 0.1299 0.0979 0.1554 0.2450 
 
 
Correlations 
Table 2 provides the univariate correlations among the regression variables. While correlations for 
variables scaled by PRC are reported above the diagonal, correlations for variables scaled by BKV are 
reported below the diagonal. Both R&D and capital expenditures are positively correlated with different 
measures of variability of future benefits. The correlations between capital expenditures and different 
measures of variability of future benefits are all larger than those of between R&D expenditures and 
variability of future benefits when the deflator is PRC. But when BKV is the deflator, only correlations 
between capital expenditures and variability between future sales revenue is larger than R&D 
expenditures and variability of future sales revenue. Nevertheless, we cannot interpret these correlations 
as marginal impacts on variability of future benefits. 
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TABLE 2  
CORRELATIONS 
 
 RNDt CapExt ADVt MVt Leveraget SD(Et+1,t+5) SD(St+1,t+5) SD(CFt+1,t+5) 
RNDt 1.000 
0.082 
<.0001 
0.008 
0.0557 
-0.213 
<.0001 
0.067 
<.0001 
0.166 
<.0001 
0.013 
0.0036 
0.100 
<.0001 
CapExt 
0.239 
<.0001 
1.000 
0.258 
<.0001 
-0.066 
<.0001 
0.345 
<.0001 
0.345 
<.0001 
0.275 
<.0001 
0.200 
<.0001 
ADVt 
0.060 
0.0557 
0.252 
<.0001 
1.000 
-0.103 
<.0001 
0.195 
<.0001 
 0.083 
<.0001 
0.151 
<.0001 
0.117 
<.0001 
MVt 
-0.072 
<.0001 
0.086 
<.0001 
-0.004 
0.3370 
1.000 
-0.275 
<.0001 
-0.424 
<.0001 
-0.235 
<.0001 
-0.372 
<.0001 
Leveraget 
-0.107 
<.0001 
0.105 
<.0001 
0.074 
<.0001 
-0.250 
<.0001 
1.000 
0.312 
<.0001 
0.373 
<.0001 
0.341 
<.0001 
SD(Et+1,t+5) 
0.234 
<.0001 
0.033 
<.0001 
0.039 
<.0001 
-0.330 
<.0001 
0.142 
<.0001 
1.000 
0.543 
<.0001 
0.704 
<.0001 
SD(St+1,t+5) 
0.063 
<.0001 
0.116 
<.0001 
0.104 
<.0001 
-0.253 
<.0001 
0.289 
<.0001 
0.556 
<.0001 
1.000 
0.725 
<.0001 
SD(CFt+1,t+5) 
0.211 
<.0001 
0.043 
<.0001 
0.052 
<.0001 
-0.358 
<.0001 
0.181 
<.0001 
0.698 
<.0001 
0.587 
<.0001 
1.000 
Pearson correlations are reported. P-values are reported below correlations. 
Correlations when variables are scaled by PRC are reported above the diagonal.  
Correlations when variables are scaled by BKV are reported below the diagonal. 
 
EMPIRICAL RESULTS 
 
We estimate the future uncertainty equation using pooled ordinary least squares regression3. We 
adjust the standard errors for heteroskedasticity, serial-, and cross-sectional correlation using a two-way 
cluster at the firm and year level which was suggested by Petersen (2009) as the preferred method for 
estimating standard errors using panel data. 
 
Earnings 
We present our results with the standard deviation of future earnings as the independent variable in 
Table 3 below. This table contains results using both PRC and BKV as the deflators. Results are in line 
with the results of Kothari et al. (2002). The coefficient estimates on R&D are 0.0866 (t-statistics of 
16.31) when PRC is the deflator and 0.0816 (t-statistics of 43.64) when BKV is the deflator. The 
corresponding average coefficient estimates on capital expenditures are 0.0264 (t-statistics of 4.48) and -
0.0057 (t-statistics of -2.30). Interestingly, when BKV is the deflator, capital expenditures seem to reduce 
the uncertainty in future earnings. An F-test for the equality of coefficients indicates that the coefficient 
on R&D is significantly larger than the coefficient on capital expenditures. We report F-values of 144.29 
when PRC is the deflator and 959.21 when BKV is the deflator. Overall, results show that, consistent with 
Kothari et al. (2002), R&D expenditures' contribution to uncertainty in future earnings is significantly 
higher than capital expenditures' contribution.  
The coefficients on control variables in the empirical model, advertising, market value and leverage, 
have their expected signs. That is the coefficients on advertising and leverage are positive while the 
coefficient on market value is negative. However, the coefficient on advertising is insignificant when the 
deflator is PRC. 
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TABLE 3 
R&D AND FUTURE EARNINGS VARIABILITY 
 
 Scaled by PRC   Scaled by BKV  
Variable 
Coefficient 
Estimate t-stat p-value 
Coefficient 
Estimate t-stat p-value 
Intercept  0.0714 104.50 
 <.0001  0.1181 157.29 
 
<.0001 
RNDt  0.0866   16.31  <.0001  0.0816   43.64 
 
<.0001 
CapExt  0.0264    4.48  <.0001 -0.0057   -2.30  0.0217 
ADVt  0.0015    0.23  0.8142  0.0165    4.15 
 
<.0001 
MVt -0.0183  -90.98  <.0001 -0.0151 
 -
71.45 
 
<.0001 
Leveraget  0.0568   31.46  <.0001  0.0320   23.35 
 
<.0001 
R-Squred 
(%) 22.75     
16.22     
F-Value 144.29  <.0001 959.21  <.0001 
SD(Et+1,t+5) is the dependent variable. t-statistics are calculated after adjusting the standard 
errors for heteroskedasticity, serial-, and cross-sectional correlation using a two-way cluster at 
the firm and year level. F-Value is to test the equality of coefficients on RND and CapEx. 
 
Sales Revenue 
We present our results with the standard deviation of future sales revenue as the independent variable 
in Table 4. Similar to Table 3, we present the estimation results using beginning both PRC and BKV as 
the deflators. The coefficient estimates, when PRC is the deflator, on R&D and capital expenditures are -
0.7519 (t-statistics of -10.79) and 2.2195 (t-statistics of 21.61), respectively. When BKV is the deflator, 
the coefficient estimates on R&D and capital expenditures are 0.1457 (t-statistics of 9.68) and 0.3481 (t-
statistics of 14.81), respectively. We report F-values of 274.49 when PRC is the deflator and 184.04 when 
BKV is the deflator to test the equality of coefficients. This indicates that the coefficient on R&D is 
significantly smaller than the coefficient on capital expenditures. In contrast to the results for earnings, 
our results for sales revenue provide evidence contrary to the notion that R&D expenditures generate 
more uncertain future benefits than investments in capital assets.  
Prior research provide evidence that demand uncertainty depresses firm investment (Bo, 2002; Fuss 
and Vermeulen, 2004) and this adverse effect of demand uncertainty on R&D investments is more salient 
than that of on non-R&D related investments (Goel and Ram, 2001). The evidence that R&D budgets are 
often determined as a percentage of firm sales revenue (Scherer, 2001; Tubbs, 2007) indicates that firms 
determine the level of R&D spending based on availability of resources. Therefore, our result that R&D 
generates less uncertain future sales revenue is consistent with our firms investing in R&D projects that 
would lead to less volatile sales revenue. 
The coefficients on control variables in the empirical model, advertising, market value and leverage, 
have their expected signs. That is the coefficient estimates on advertising and leverage are positive while 
the coefficient on market value is negative. And all of the coefficient estimates are statistically significant. 
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TABLE 4 
R&D AND FUTURE SALES REVENUE VARIABILITY 
 
 Scaled by PRC   Scaled by BKV  
Variable 
Coefficient 
Estimate t-stat p-value 
Coefficient 
Estimate t-stat p-value 
Intercept   0.4485   45.45  <.0001  0.5048 79.23  <.0001 
RNDt  -0.7519  -10.79  <.0001  0.1457 9.68  <.0001 
CapExt   2.2195   21.61  <.0001  0.3481 14.81  <.0001 
ADVt   0.6880    5.24  <.0001  0.4013 10.00  <.0001 
MVt  -0.1022  -38.71  <.0001 -0.0824 -45.11  <.0001 
Leveraget   0.9463   28.28  <.0001  0.6349 38.32  <.0001 
R-Squred 
(%) 18.82     13.64     
F-Value 274.49  <.0001 184.04  <.0001 
SD(St+1,t+5) is the dependent variable. t-statistics are calculated after adjusting the standard errors 
for heteroskedasticity, serial-, and cross-sectional correlation using a two-way cluster at the firm 
and year level. F-Value is to test the equality of coefficients on RND and CapEx. 
 
Operating Cash Flows 
We present our results with the standard deviation of future operating cash flows as the independent 
variable in Table 5. Similar to Tables 3 and 4, this table also contains results using both PRC and BKV as 
the deflators. The coefficient estimates on R&D are 0.0136 (t-statistics of 2.78 when PRC is the deflator 
and 0.0765 (t-statistics of 38.26) when BKV is the deflator. The corresponding coefficient estimates on 
capital expenditures are 0.0991 (t-statistics of 16.82) and 0.0013 (t-statistics of 0.48). The results of our 
analysis with cash flows are not robust to the choice of the deflator. The implication, when PRC price is 
the deflator, is that capital expenditures generate significantly more uncertain cash flows than R&D 
expenditures. The significance is indicated by an F-value of 147.65. The results, when BKV is the 
deflator, indicates that R&D expenditures generate significantly more uncertain cash flows than capital 
expenditures evidenced by an F-value of 753.28. Further, the coefficient estimate on capital expenditures 
is statistically insignificant. Overall, we cannot conclude that R&D expenditures' contribution to 
uncertainty in future operating cash flows is significantly higher than capital expenditures' contribution or 
vice versa. 
Results, when PRC price is the deflator, are consistent with the evidence that higher cash flow 
volatility leads to lower average levels of investment in capital expenditures, R&D, and advertising 
(Minton and Schrand, 1999). And this relationship is strongest for R&D after controlling for cash flow 
levels. This would imply that to the degree that expected cash flow volatility is accurately predicts 
realized volatility; firms would invest in R&D projects that would lead to less volatile cash flows. And 
the results, when BKV price is the deflator, might be a manifestation of book value of equity being 
understated due to the accounting convention of expensing R&D expenditures. 
In contrast to our results PWZ (2011) finds that R&D expenditures' contribution to uncertainty in 
future operating cash flows is higher than capital expenditures' contribution. We don't believe their results 
are comparable to ours because there are several differences between their study and ours. First, they 
adjust reported cash flow measure by adding back R&D and advertising. Second, they do no test the 
significance of the difference of coefficient on R&D and capital expenditures and they do not conclude 
that they are significantly different. And last, a minor difference, we use per share variables while they 
use levels of variables. 
Similar to Table 4, the coefficients on control variables in the empirical model, advertising, market 
value and leverage, have their expected signs. That is the coefficient estimates on advertising and 
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leverage are positive while the coefficient on market value is negative. And all of the coefficient estimates 
are statistically significant. 
 
TABLE 5 
R&D AND FUTURE OPERATING CASH FLOW VARIABILITY 
 
 Scaled by PRC   Scaled by BKV  
Variable 
Coefficient 
Estimate t-stat p-value 
Coefficient 
Estimate t-stat p-value 
Intercept  0.0734  109.66  <.0001  0.1238 158.99  <.0001 
RNDt  0.0136    2.78  0.0054  0.0765   38.26  <.0001 
CapExt  0.0991   16.82  <.0001  0.0013    0.48  0.6300 
ADVt  0.0221    3.12  0.0018  0.0251    5.93  <.0001 
MVt -0.0146  -75.23  <.0001 -0.0172  -77.15  <.0001 
Leveraget  0.0582   29.72  <.0001  0.0444   28.44  <.0001 
R-Squred 
(%) 20.98     17.78     
F-Value 147.65  <.0001 753.28  <.0001 
SD(CFt+1,t+5) is the dependent variable. t-statistics are calculated after adjusting the standard 
errors for heteroskedasticity, serial-, and cross-sectional correlation using a two-way cluster at 
the firm and year level. F-Value is to test the equality of coefficients on RND and CapEx. 
 
CONCLUSION 
 
The FASB’s ASC 730-10 notes that the trade-off between relevance and uncertainty of future benefits 
is a major consideration in expensing of R&D expenditures. The trade-off suggests balancing the demand 
for value-relevant information by equity investors, with the demand for information that has 
representational faithfulness about future benefits, by debt holders and other stakeholders. KLL (2002) 
provides evidence in support for the uncertainty of future benefits from R&D expenditures. In this study, 
we further explore the uncertainty of future benefits of R&D expenditures relative to capital expenditures. 
KLL (2002) used future earnings variability as a proxy for the uncertainty of future benefits. In addition 
to future earnings variability, we consider future sales revenue variability and future operating cash flow 
variability as a proxy for the uncertainty of future benefits. 
Similar to KLL (2002), our results support the notion that R&D investments generate more uncertain 
future earnings compared to capital expenditures. However, our analysis for uncertainty in future sales 
revenue and future operating cash flows reveal a different picture. In terms of sales revenue, R&D 
investments generate less uncertain future benefits compared to capital expenditures. And in terms of 
operating cash flows, we cannot conclude that R&D expenditures' contribution to uncertainty in future 
operating cash flows is significantly higher than capital expenditures' contribution or vice versa. To the 
degree that expected future uncertainty accurately predicts realized volatility, our results are manifestation 
of the fact that managers reduce their outlays in R&D more than capital investments when they expect 
uncertain demand. 
We believe that our study contributes to the current debate over accounting for R&D expenditures. A 
number of studies provide evidence that the capitalization of R&D would help in making the balance 
sheet more value relevant for share prices (e.g., Lev and Sougiannis, 1996). These studies provide 
standard setters with useful information on the relevance dimension of the relevance-faithful 
representation tradeoff. Our study provides evidence that is contrary to the notion that R&D expenditures 
generate future benefits that are more uncertain than benefits from expenditures in PP&E. Therefore, we 
provide standard setters with a relative measure of the faithful representation of future benefits component 
of the relevance-faithful representation trade-off. 
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ENDNOTES 
 
1 We repeat our analysis with sales and earnings over the period included in Kothari et al. (2002). The results, not 
tabulated in the paper, are comparatively similar. 
2 The decile portfolio average earnings variability is calculated using data for surviving firms only. 
3 Similar to KLL (2002), we also estimate future uncertainty equation for each year from 1987 to 2005 and calculate 
the summary statistics from these thirty-four regressions. The results, not tabulated in the paper, are comparatively 
similar. 
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